sgusers2的部落格

早報記者張郁文與秦皇島天業通聯重工股份有限公司(天業通聯，迷你倉新蒲崗002459)實際控制人不斷減持相對應的是，華建興業投資有限公司(以下簡稱“華建興業”)半個月來連續增持天業通聯。截至昨日，華建興業與天業通聯實際控制人胡志軍及其一致行動人朱新生持股比例相差7.56個百分點。天業通聯昨日午間公告顯示，截至9月11日，華建興業所持天業通聯無限售條件流通股3139.87萬股，占總股本的14.12%。此外，天業通聯還同時披露，華建興業2500萬股股份質押給北京首創融資擔保有限公司，該筆股份占其持有總量的79.62%。此前的9月4日晚間，天業通聯公告稱，華建興業分別于2013年8月30日、2013年9月4日通過深圳證券交易所大宗交易系統買入公司股份987.80萬股、119.82萬股，分別占總股本的4.44%、0.54%。該次增持後，華建興業持有天業通聯2218.62萬股，占總股本的9.98%。而就在9月9日，天業通聯有兩筆合計921.25萬股的大宗交易，買入方應為華建興業。華建興業首次舉牌天業通聯是在今年的8月26日。根據天業通聯彼時的公告，華建興業于2013年8月26日通過深交所大宗交易系統買入天業通聯1111.00萬股，占總股本的5.00%。不過就在華建興業上述舉牌的同日，天業通聯實際控制人之一的胡志軍同樣通過深交所大宗交易減持天業通聯111迷你倉出租.00萬股，占總股本的5.00%，減持的股份數與華建興業一致，由此判斷，華建興業應接手了胡志軍所賣出的股份。作為天業通聯實際控制人之一的胡志軍於今年2月已辭去副董事長等職，且不再擔任任何職務，在6個月的禁售期滿之後，其連續減持天業通聯。除了上述減持外，其在8月30日再度減持上市公司，該次減持之後，胡志軍持有天業通聯1647.88萬股，兩次減持比例合計達到其所持股份50%。值得一提的是，8月30日，天業通聯另一名實際控制人朱新生也減持123.94萬股，占總股本的0.56%。減持後朱新生、胡志軍合計持有天業通聯4819.70萬股，占總股本的21.68%。可查的資料顯示，華建興業為中國華建投資控股有限公司全資子公司。中國華建投資是一家PE色彩濃厚的企業，以房地產開發和股權投資為主業的企業，並同時經營酒店、旅遊、物業管理、房地產經營策劃等相關行業。中國華建董事長為何志平，中國華建現為天音通信控股股份有限公司(天音控股，000829)第二大股東，持股比例為9.55%。此外，主營為裝備製造的天業通聯近來業績虧損嚴重。今年上半年，天業通聯淨利潤虧損為5878.27萬元，雖較上年同期少虧2613.33萬元，但其同時預計今年三季度末淨利潤將虧損6000萬-6800萬元，虧損較上半年進一步擴大。不過，2012年前三季度，天業通聯虧損達到1.25億元。迷你倉

　【記者陳藝珠海報導】第一屆中國國際馬戲節形象大使「小漁女」選拔活動日前正式啟動，新蒲崗迷你倉從九月十五日開始接受報名。凡家住珠海、有一定藝術特長的小學一年級到三年級的中國籍在校小女生，都可以自願報名參加選拔。　第一屆中國國際馬戲節將於十一月二十日至十二月一日在珠海橫琴長隆國際海洋度假區舉行。為此，馬戲節執委會辦公室聯合珠海市文體旅遊局、市教育局，決定在全市範圍內舉辦馬戲節形象大使「小漁女」選拔活動，九月十五日開始接受報名，十月十九日進行最終選拔決賽。據介紹，選拔活動將推廣「人與動物和諧共處」、「兒童是馬戲的未來mini storage等理念，充分展示珠海小朋友多才多藝和健康、積極、向上的面貌，並契合馬戲節「馬戲盛會，歡樂珠海」的主題。　據瞭解，此次選拔活動分報名、海選、賽區選拔、晉級賽、複賽和決賽六個階段，共設置香洲賽區、金灣賽區、斗門賽區、高新賽區、高欄港賽區等五個賽區分別進行比賽，決出十名小選手進入決賽。最終將評選出第一屆中國國際馬戲節形象大使「小漁女」和其他單項特別獎項。「小漁女」將有機會參與馬戲節推介會、出席公益演出和馬戲節各類儀式等，作為馬戲節形象大使參與到各類宣傳活動當中；在馬戲節的各個宣傳平台上也將體現「小漁女」形象。◇self storage

　【本報記者陳良安南投報導】南投縣社區營造據點在縣政府積極扶植與媒合下，mini storage10日特別邀集清境社區發展協會與南投縣民俗音樂發展協會，在清境農場的青青草原上練習；兩個營造點成員透過絲竹音樂的合作，演奏出彝族酒歌、月亮升起來等民族音樂，頓時讓草原上充滿邊疆民族風味，而悠揚的國樂聲、節奏優雅的舞步和高亢的歌聲，更是吸引許多遊客駐足欣賞。　縣self storage文化局副局長張怡芬表示，清境社區與音樂協會都是文化局長期扶植，相當具有活力的協力型社區營造據點，今年文化局首次媒合社區進行地方文化特色的開發與呈現，透過少數民族與絲竹音樂的串連和合作，來呈現不同特色的文化風貌，也讓各個營造點彼此能有交流和互動。楊桂蘭女士說，今年的清境火把節，將會於10月25日於清境國小大操場舉行，歡迎大家一起來參與。迷你倉

　　中新網9月12日電 據澳洲新快網報道，迷你倉出租新州州長奧法拉(Barry O'Farrell)和旅遊廳長蘇里斯(George Souris)周三(11日)表示，中國已成為新州旅遊市場的主要國家，來自中國遊客人數首次超越新西蘭。　　奧法卡指出，中國遊客在新州住宿晚數和消費額，均高踞國際遊客首位，貢獻良多。他說：“最新國際遊客調查報告顯示，今年上半年，從中國來到新州的遊客達39.6萬人，而來自新西蘭的則為38.6萬人。數字顯示，到訪新州的中國遊客人數增加18%，為新州經濟注入 13億元收益。這些數字鞏固了新州作為中國遊客訪澳首選州份的地位，我們吸納了61.2%來澳的中國遊客。　　奧法拉表示，他今年早些時候訪問中國時，曾許迷你倉要使新州成為中國遊客來澳的優先選擇，現在很高興看到這一目標得以實現。他認為新州政府採取的方針奏效，熱切歡迎中國遊客來到新州。　　蘇里斯則指出，到訪新州的中國遊客強勁增長，證明新州政府用以增加中國遊客數量的策略有效。他說今年早前推出的新州政府中國遊客訪澳策略，旨在進一步增加中國遊客，好使2020年在新州住宿遊客的消費額能增加一倍。現在當局已經陸續看到成果，中國南方航空公司已宣佈，從10月起每天將有一班航機從A330升格為A380，從而增加廣州往來悉尼航線每年的座位數量。　　蘇里斯說：“旅遊業是新州經濟重要的一環，目前取得的這些成果有助政府落實打造新州為遊客來澳首選目的地的許諾。”標簽：中國 新州 蘇里斯 遊客 州政府儲存倉

　　上午，迷你倉新蒲崗“美滿一生”京味婚慶文化消費節�動。這是市商務委針對婚慶市場相關商品推出的跨業態聯合大型促消費活動。　　據悉，本次消費節“跨界”吸納了珠寶首飾、百貨、家居、家電連鎖賣場、婚紗攝影、婚宴酒店、旅遊7大行業，聯合促銷的企業共16家，包括菜百、工美、王府井百貨集團、西單商場、資和信百貨、集美家居、百安居、北京蘇寧、國美、北京千禧大酒店、伊迷你倉出租海參館、三段錦視覺機構、25度攝影、北青旅、海洋國旅東四十條店、全程合作網站喜事網。　　據悉，2013京味婚慶文化消費節期間，參與活動的16家企業將整合內部資源，制定999元、1999、2999，直至99999元的“天長地久優惠促銷套餐”，該套餐根據新婚消費具體情況，可基本滿足一對新人的新婚需求。(記者竇媛媛)標簽：婚慶 京味 北京 百貨 套餐迷你倉

PARIS, September 11, 2013 /PRNewswire/ --Gameloft, a leading global publisher of digital and social games, today at the Intel Developer Forum 2013 announced with Intel, their plans to enhance upcoming Gameloft titles for Android platforms using Intel architecture.迷你倉"We are thrilled to optimize our upcoming games for new Android platforms running Intel architecture and once again expand our game catalogue to new high-performance smartphones and tablets," states Gonzague De Vallois, senior vice president of Publishing at Gameloft. "Intel's innovative hardware platforms help us unleash our development capabilities for even greater creativity and reach new audiences.""Gameloft games are visually stunning and will help create immersive gaming experiences on Intel-based platforms," said Doug Fisher, corporate vice president and general manager, Intel Software and Services Group. "With top gaming companies like Gameloft investing in Intel Architecture, it's clear there is no better time for developers and consu儲存ers alike to choose systems running the latest Intel processors."About Gameloft:A leading global publisher of digital and social games, Gameloft(R) has established itself as one of the top innovators in its field since 2000. Gameloft creates games for all digital platforms, including mobile phones, smartphones and tablets (including Apple(R) iOS and Android(R) devices), set-top boxes and connected TVs. Gameloft operates its own established franchises such as Asphalt(R), Order & Chaos, Modern Combat or Dungeon Hunter and also partners with major rights holders including Universal(R), Illumination Entertainment(R), Disney(R), Marvel(R), Hasbro(R), FOX(R), Mattel(R) and Ferrari(R).Gameloft is present on all continents, distributes its games in over 100 countries and employs over 5,000 developers.Gameloft is listed on NYSE Euronext Paris . Gameloft is traded OTC in the US .For more information, press only:Heather Cosby PR Manager +1(415)615-0520 Email: heather.cosby@gameloft.comGameloft新蒲崗迷你倉

剛過完14歲生日，儲存阿里巴巴又有了大動靜。昨日，阿里旗下天貓宣佈�動“品牌旗艦店升級”計劃，從簡單的線上銷售模式，向“社交商務”模式轉變。而實際上，阿里的兩大對手——百度和騰訊，已在社交商務領域先行一步。隨著阿里的發力，BAT在社交商務領域的戰爭已經一觸即發。“如果我們不變，有一天就跟不上了”“天貓將從銷售平台走向消費者連接平台，從電子商務走向社交商務，關鍵就是互動。”昨日，天貓旗艦店升級計劃正式亮相，升級後的旗艦店可以成為品牌傳播和銷售合一的“品牌站”，幫助商家建立品牌和消費者的連接，目前首批44家品牌店已經上線。距離“雙11”還剩2個月，而天貓選擇此時發佈旗艦店升級計劃，頗有深意。日前，有媒體報道稱，今年“雙11”天貓淘寶的銷售目標是500億元，較去年增長160%。天貓副總裁王煜磊直言，現在的天貓只解決了購買這一個問題。而消費者對電商多年來“貨架式購物”已經表示不滿。在和品牌商溝通時也發現，最具營銷實力的品牌，也已不滿于單純銷售的模式，希望能建立除旺旺外更多其他形式與消費者的互動方式。“我們一定要變，如果我們不變，有一天就跟不上了。”談及從電子商務向社交新蒲崗迷你倉務上的轉變，王煜磊表示，商務是阿里的核心基因，與社交結合後，誰跑得最快，誰提供的產品服務更能符合消費者的需求，誰才能吸引更多的品牌商和消費者。三巨頭在社交商務短兵相接事實上，雄心勃勃的阿里在社交領域的布局已經發力。9月10日，阿里宣佈成立網絡通訊事業部，由原來的旺信業務和來往業務組成，由阿里新任CEO陸兆禧親自掛帥移動業務。9月9日，微博淘寶版開放，所有賣家等級在五鑽以上的淘寶商戶，都可以在旺鋪後台免費開通這一服務。數據顯示，上線一個多月以來，測試賣家所發佈的帶商品信息的微博互動量是未使用微博淘寶版賣家的6倍；測試期間，微博淘寶版的導流數量提高了500%。而早已先行一步的百度和騰訊顯然更注重向其用戶進行電子商務的引導。繼百度微購之後，近日百度旗下問答社區百度知道已于日前低調上線了商品導購平台“買什麼”，為用戶提供網購決策服務。騰訊當然更不會放棄直接能轉化成利潤的電子商務。騰訊上半年業績報告顯示，受電子商務營收大增拉動，上半年實現淨利潤77.554億元，比去年同期增長27.7%。而微信5.0推出的微信支付，也讓騰訊構想的手機全能錢包變成了現實。晨報記者 韓元佳mini storage

上周去了一趟日本，儲存倉為優秀的業務人員舉行頒獎典禮，也慰勞大家的辛苦。有一天，在等新幹線的候車站，一幅巨大的海報看板吸引我的注意。看起來是旅遊風光的背景上，寫著「大人ソ休日」幾個字。我原以為只是鼓勵旅遊、擴大內需的廣告，再仔細讀旁邊的傳單，發現這原來是為銀髮族設計的整合方案，除了搭乘新幹線有折扣，還有其他的生活休閒資訊與課程、活動，豐富退休族的生活。 這樣異業整合，將人口老化問題轉為商機的點子，讓我想起出發前，在一場與醫院院長們的座談中，聊到如何透過異業結盟，化解大家擔心的醫療、健保資源，以及長期照護的問題，並且開拓新的機會。 醫療與人命息息相關，是每個人都不會掉以輕心，無論國家、機構或個人都必須、也願意投入資源的事。但我們的生活有許多層面，醫療不是單獨存在、與其他需求無關的事。因此，從人們生活中的相關面向著手，就有機會改變人的行為，緩解問題。 例如，過去的保險業慣例是，在急診室待超過幾個小時以上，才可以申請理賠。結果，有些人即使已經可以返家休息，也要在急診室撐到得以理賠的時數，間接造成了急診室人滿為患的原因之一。除了醫療資源的浪費，更可能因此延誤其他更需要照顧的病人就醫。 同樣的是治療疾病的方法。傳統的保險，常常以住院為條件、或以住院天數計算理賠，造成很多不需住院的病人堅持住院。但是醫療技術不斷演進，許多疾病或療程不用住院，就可以有更好、更快、讓病人較不痛苦的方式治療。若為了理賠執著於住院，反而本末倒置。為此，我們推出依疾病種類作為理賠依據的商品，保戶一旦罹病，就可以申請一筆保險金，可以跟醫生討論，根據他個人的生活型態以及需求、病況，可以採取哪些讓患者更舒服的治療方式，不必拘泥是否住院，反而造成醫療體系與家人更大的負擔。 在面對人口老化問題時，雖然關於長期照護的相關法規還沒有完全定案，我們也已經開始結合異業資源。 例如，我們運用散布在全台灣各迷你倉價錢的業務人力從事義工服務，有的幫助老人送餐，有的探望老人或帶他們出去走走，甚至協助募款興建老人社區醫療體系，盡己所能地在各地協助緩解人口老化問題。 以上只是運用保險和醫療的結合，一起改變社會問題。在企業經營裡，還有很多異業相互借鏡、合作與成長的好機會。例如，這一次在日本，我們邀請旅日棒球國手陽岱鋼參加頒獎典禮，除了業務尖兵大受激勵，他還在現場拍賣一顆簽名球，不到幾秒鐘，就募到新台幣60萬元，捐給補助經濟弱勢族群醫療費用的「幸福基金」。 在同一場活動中，我們也邀請在台灣知名的建築師安藤忠雄，用他的經歷啟發大家追求挑戰的勇氣與毅力，深獲好評。許多同仁反映，比聆聽同業的經驗談更有收穫。 我們常邀請各行各業的頂尖人士到公司演講，也在各種活動中置入異業學習的要素。例如，我們跟王品學習，統計客戶來電是抱怨還是讚美的數量，用以了解客戶的感受，提升了服務品質；我們帶業務夥伴到東京迪士尼親身體認如何給客戶「愉悅的使用經驗」，也到多次贏得服務大獎的銀行、便利超商學習他們的服務心法，甚至還探索跨業合作案。 現代生活緊湊，人們的時間有限，許多需求、產業的界線逐漸模糊，所有的企業都在跨業競爭，爭取客戶的注意力。在這種環境下，更需要不同行業智慧與經驗的交流、整合，一起思考，可以如何透過合作改變消費者的心態與行為，不僅開拓新的成長機會，更合力解決整個體系面臨的問題。 不過，我們的政府體系與監理仍然以產業劃分界線，有時甚至如楚河漢界，難以越雷池一步。這導致當今許多重大的議題，例如本文提到的長期照護、健保等，因為跨越不同部門管轄範圍，而難以形成共識，延宕政策定案或是錯過解決問題的最佳時間。 就像異業的結合日趨盛行，政府不妨也多創造平台或機會，增進政府間跨部門的協調與合作，多嘗試、鼓吹跨界的管理與整合，並且邀集更多業界共同參與，相信很多難題都有機會迎刃而解。（作者為資深企業經理人）迷你倉最平

博仁大學(DPU)位於泰國首都曼穀,是教育部重點推薦留學院校,現有在校生3萬多人,學士學位專業60個,碩士學位學科19 個,博士學位學科6個。是泰國一所取得ISO9001:2000國際質量體系認證的大學。 高中起點4年本碩連讀,專科起點2.self storage5年本碩連讀,本科起點1年碩士,碩士專業有:工商管理、教育管理,本科專業有:工商管理與國際貿易、會計與金融、旅遊與酒店管理,全日制學習方式,免試入學,中英雙語授課,入學無語言要求,學歷學位獲教育部認證 。泰國高等教育國迷你倉化水平較高,課程設置、教學體制與歐美同步,採取學分制。而在留學成本上,泰國遠遠低於其他歐美、亞洲國家。此次招生面向廣西專科畢業生直讀2.5年本碩連讀,本科畢業生直讀1 年碩士,高中畢業生可直讀4年本碩連讀雙語國際班,本次碩士招生10 月中旬入學,報名提交材料即可申請博仁大學錄取信。0771-6724966/998 6739346/35 46769523/663 .dpubkk.com 地址:廣西大學外國語學院中國東盟國際教育研究與教學中心(國內英泰語授課點)文件倉

Drug approval and tendering system in spotlight, report He Na and Jiang Xueqing in Beijing, and Han Junhong in Changchun Sun Xiaoyan used to be a frequent visitor to hospitals, but not as a patient.self storageShe maintains close links with a number of doctors and nurses and warmly calls them "brothers" and "sisters", and her close relatives and friends always get to see a doctor without waiting in line.The 34-year-old independent pharmaceutical sales representative from Nong'an county in Jilin province knows exactly how China's medical system works, and she also knows how to get rich from it.However, Sun hasn't visited any hospitals for the past two months. Instead of paying visits or inviting doctors and nurses for dinner or entertainment, she has been killing time at home, watching movies on her computer and playing games on her phone.She always carries two smartphones in her bag. The one with the white cover is for personal use, while the black one is for work. However, right now Sun has turned off the black phone.She said she has no idea when she will return to the hospitals, but it won't be until after the "two crackdowns".The first of the crackdowns Sun mentioned is an anti-corruption campaign aimed at the medical sector. It was started in early July following a scandal involving the Chinese unit of British pharmaceutical giant GlaxoSmithKline, which is being investigated for suspected bribery and tax-related offenses.An initial police investigation found that GSK China increased its sales by offering bribes to doctors and hospitals, thus pushing up drug prices and undermining patients' interests.Second, the State Administration for Industry and Commerce announced on Aug 13 that a campaign focusing on illegal competition, especially bribery in the medical industry, will run from Aug 15 until the end of November.Insiders believe the investigations will initially target foreign pharmaceutical companies before being expanded nationwide."I heard that plainclothes police are monitoring major hospitals, and several pharmaceutical sales reps have already been detained," said Sun.In the wake of the GSK allegations, which the Chinese authorities claim company executives have privately admitted, the National Development and Reform Commission ordered 60 drug manufacturers, including 27 foreign companies, to submit their cost and pricing files for review.Experts believe that the anti-corruption drive triggered by the case will embrace the medical industry nationwide."The allegations of bribery are not intentionally aimed at foreign pharmaceutical companies. No matter if the companies are Chinese or foreign, problems such as this are common in the drug distribution process. That should sound the alarm for all pharmaceutical companies and doctors," said Zhang Yanling, president of the Chinese Medical Doctor Association.The association is planning to establish a method of evaluating medical practitioners based on their professional ethics. Those found to have seriously violated the code of conduct will be placed on a blacklist and will not be recommended for hire by medical institutions.Deep-rooted problems Song Shan, a regional manager at a large pharmaceutical plant in Guangdong province, who has worked in the medical industry for more than two decades, said the problems are deep-rooted."Foreign pharmaceutical enterprises are no different from their domestic peers. If they want to survive and make a profit, they need to go through the channels of hospitals and doctors," he said."Medical resources in China are highly concentrated in, and monopolized by, the large public hospitals. Therefore, the doctors at these hospitals naturally exercise great power," he said.Gaining the confidence of doctors is not easy because they are now very cautious, so a lot of businesses hire public-relation experts to train their sales reps, he said.According to Song, besides providing kickbacks for medical staff, the reps even extend their largesse to the families of doctors and hospital chiefs and, if the customer is deemed important enough, greater temptations, such as overseas travel, will be offered."Most of each kickback payment ends up in the doctor's pocket. Compared with the doctors, the amount that the manufacturers and sales representatives receive is much lower," he said.Song recalled taking his son to a public hospital in May because the boy was running a fever. The doctor prescribed three boxes of a foreign-brand antipyretic at a cost of 70 yuan ($11) per box."What made me angry was that the drug he prescribed can have a serious adverse effect on children's growth and should not be recommended for kids. I pounded on his desk and questioned the prescription. When he learned that I was a drug industry professional, the doctor's attitude underwent a U-turn and he prescribed two boxes of a much cheaper domestic drug," he said.Zhang Shuang, a manager at a large State-owned pharmaceutical company in Jilin, said, "As pharmaceutical manufacturers, we hate commercial bribery. However, there is no rule of fair competition in our market, so it's almost impossible to get your drugs on the prescription list if you don't pay high kickbacks." Long profit chain He Dong, general manager of a large pharmaceutical manufacturer in Changchun, said commercial bribery in the medical sector involves a long profit chain and the sales reps are at the lowest level. Even if the police arrested every representative, good and bad, or abolished the job, bribery would still exist and another group of people would rapidly appear under a different job title and commit the same acts."The crackdown on commercial bribery is necessary and timely, but just focusing on the sales representatives is putting the cart before the horse," he said.While He is worried that the crackdown may force bribery further underground, he stressed that the practice is only the tip of the industry's iceberg of corruption.He's words were echoed by Song, who said the really serious problems lie in the approval process for new drugs and the bidding process for government and hospital drugs."Too many government departments are given rights over drug approval and tender. Under the current bidding system, drugs that provide effective treatment at a reasonable price are not guaranteed to win approval or be listed in the local basic drug category, or the hospital drug category. Good relations with government departments always carry more weight," Song said.That cozy relationship is also one of the reasons companies prefer to cultivate good relations with government departments rather than investing time and energy in the research and development of new drugs, he said."The involvement of so many government departments equals zero management. Sometimes, these departments intentionally erect barriers if drug companies forget to shower them with gifts or money," he said."A new medicine needs at least four to five years of research and development before it can be put on the market. Without close relationships with government departments, pharmaceutical manufacturers seldom dare to invest in new drugs. To save on costs, many manufactures will make small changes to existing treatments, give them a new name and then apply fo迷你倉 approval," said He.In the long run, the system is harmful to innovation and development across the entire industry. "It's essential that we introduce an independent nongovernmental body to oversee the approval of new drugs and the bidding process for the basic drug category in each province. Government departments should only be involved to ensure that supervision is correctly carried out," he said.Low hospital investment Pharmaceutical sales have been rising rapidly in China. Total sales reached 600 billion yuan last year, and average annual growth has exceeded 20 percent during the past five years, compared with 0.3 percent in the developed markets, according to statistics from the industry researcher IMS Health."Most hospitals follow their own bidding rules when deciding which drugs to buy and prescribe. When drugs are of similar quality and effectiveness, the one with the lower price will always win the bid, but there are no strict rules demanding that hospitals must prescribe those low-priced drugs to patients," said Guo Fanli, an analyst at China Investment Consulting Co."Under the system where hospital expenditure is covered by medical revenues, doctors prescribe expensive medicines so they can rake off a decent kickback. The manufacturers overinflate the market prices of their drugs to leave more room for discounts and to ensure the doctors receive good kickbacks. Expensive drugs also increase hospital revenues because the patients pay so much for them. That's why expensive drugs sell better than cheap ones in hospitals," he said.Zhang said a lack of government investment in medical institutions and the low salaries earned by Chinese doctors, compared with their Western peers, simply exacerbate the problem.In 2011, China's total healthcare expenditure was 2.43 trillion yuan, equivalent to just 5.15 percent of gross domestic product, according to statistics from the National Health and Family Planning Commission.Generally speaking, government funding covers around 20 percent of a public hospital's annual expenditure, but the percentage varies from one hospital to another, said Zhang.During a previous interview with China Daily, Chen Zhongqiang, professor at the orthopedic department of Peking University Third Hospital, said government funding amounts to just 5 percent of the hospital's annual revenue which, in 2011, was 2.25 billion yuan."I hope the bribery scandals will prompt the government to accelerate healthcare reform by increasing investment in public hospitals and raising doctors' salaries to a reasonable level that matches their skills and hard work," said Zhang.Guo Fanli said the GSK case is unlikely to affect the development of China's medical industry. On the contrary, the case will boost medical companies' share prices because the warning the government has delivered will force some manufacturers to cease illegal competition, which would help to clean up the competitive environment.No easy solutions He called on the authorities to enact new laws and strengthen the existing rules to ensure that violators are heavily penalized.Many experts have called for the separation of medical care services and drug sales in hospitals, saying that such a move would result in a severing of the links between service providers, the purchasers of medicines and the pharmaceutical companies, thereby reducing the opportunity and risk of collusion.Guo was of the same opinion, but warned that under the current system, whereby hospital expenditures are reliant on the sales of medicines, there are plenty of interested parties, meaning the problem can't be solved overnight."I hope the investigation into GSK is the beginning of the government's determination to root out corruption in medical industry, but equally, I hope it's not the end," Guo said.Contact the writers at hena@chinadaily.com.cn and jiangxueqing@chinadaily.com.cn First person talk Li Tao, 60, a physician at a public hospital in Northeast China's Jilin province.As far as I know, almost all the doctors prescribe drugs provided by sales reps on condition they receive a large kickback.In addition, many doctors in outpatient departments prescribe "high-kickback" drugs, which account for most of the medicines used in hospitals.Generally, departmental directors and vice-directors get most of the bribes, but the other doctors and nurses also receive something every month. The money is distributed on a sliding scale in order of their importance.Cure sought for medical sector's ills If it's a special day for a director or senior practitioner, the sales representatives are usually the first to congratulate them by sending "greetings", such as store cards or gifts. Sometimes they invite the entire department to dinner or to spend a weekend at a fancy entertainment venue.Compared with drug kickbacks, red envelopes (a form of petty bribery in China) usually only contain small amounts of money and are easily traceable.However, most of the doctors in my hospital refuse red envelopes, and their "gray income" comes mainly from kickbacks instead.Experienced sales representatives don't usually visit hospitals, but if they do they never talk about medicine and kickbacks. They send gifts directly to people's homes.Sales representatives are also familiar with the close family members of the doctors and use them as conduits for gifts and cash.Very few bribes come in the form of hard cash. Instead, they are usually transferred to unmarked bank accounts.We mainly prescribe domestic drugs. Foreign medicines only account for a small proportion of the total because they are comparatively expensive and aren't available through medical insurance, so few patients agree to use them.Li Tao spoke to He Na and Han Junhong.Zhang Shuang, sales manager at a large pharmaceutical enterprise in Changchun, Jilin province My company doesn't employ full-time sales reps. Instead we only use freelance salespeople and their relationship with us is limited to quarterly visits, when they come to get their own kickbacks.Cure sought for medical sector's ills We only have one requirement when choosing salespeople - they must be familiar with the hospital system and understand the ways in which they can promote our products to more than 80 percent of the hospitals within a certain district.Cutthroat competition will only lead to a lose-lose situation, so to prevent a full-scale price war, we usually only assign one leading representative to each district. Their performance is assessed on a quarterly or semiannual basis and they are replaced if they fail to meet the required sales volume over two consecutive assessment periods.People with a close relationship with government staff or who are relatives of high-fliers in the medical system are our preferred choices of reps.Out of all the drugs and related equipment we produce, the sales reps only choose those with wide profit margins because it encourages hospitals and doctors to put in orders.Take cannulas - the reedlike pipes that allow fluids to be injected into or drained from the body - for example. Our factory price is 16.8 yuan ($2.75) each, but the reps sell them at 24.45 yuan apiece, while the hospital price is 50.45 yuan.Zhang Shuang spoke to He Na and Han Junhong.文件倉